Alkahest, Inc.: Clinical Trials

8 completed, 2 terminated. 10 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 8, Terminated 2

Follow Alkahest, Inc.: new trials by email

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) AKST4290, Placebo - Diabetic Retinopathy	Phase 2	Terminated	Alkahest, Inc.	3	2021-08-17	2023-11-01
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid Mometasone furoate, AKST4290, Placebo - Pemphigoid, Bullous	Phase 2	Terminated	Alkahest, Inc.	6	2020-01-30	2023-09-14
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD AKST4290, Placebo, Aflibercept - Neovascular Age-related Macular Degeneration	Phase 2	Completed	Alkahest, Inc.	107	2020-01-28	2022-10-26
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment AKST4290, Placebo - Parkinson Disease	Phase 2	Completed	Alkahest, Inc.	110	2020-01-16	2022-10-10
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty GRF6021, Placebo - Postoperative Recovery	Phase 2	Completed	Alkahest, Inc.	38	2019-07-12	2024-03-13
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease GRF6019, Placebo - Severe Alzheimer Disease	Phase 2	Completed	Alkahest, Inc.	26	2019-01-15	2021-01-27
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment GRF6021, Placebo - Parkinson Disease	Phase 2	Completed	Alkahest, Inc.	79	2018-11-12	2022-05-09
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration ALK4290 - Wet Age-related Macular Degeneration	Phase 2	Completed	Alkahest, Inc.	26	2018-04-20	2020-12-22
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease GRF6019 - Alzheimer Disease, Mild to Moderate Alzheimer Disease	Phase 2	Completed	Alkahest, Inc.	47	2018-04-16	2021-01-29
Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration ALK4290 - Wet Age-related Macular Degeneration	Phase 2	Completed	Alkahest, Inc.	30	2018-04-04	2020-12-16

Conditions studied

Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Dementia (3)  ·  Mental Disorders (3)  ·  Nervous System Diseases (3)  ·  Neurocognitive Disorders (3)  ·  Neurodegenerative Diseases (3)  ·  Alzheimer Disease (2)  ·  Parkinson Disease (2)  ·  Autoimmune Diseases (1)  ·  Diabetic Retinopathy (1)  ·  Eye Diseases (1)  ·  Macular Degeneration (1)  ·  Movement Disorders (1)  ·  Pemphigoid, Bullous (1)

Interventions

Mometasone Furoate (1)  ·  Saline Solution (1)  ·  aflibercept (1)

Countries

United States (7)  ·  Germany (3)  ·  Hungary (3)  ·  Poland (2)  ·  Australia (1)  ·  Estonia (1)  ·  France (1)  ·  Slovakia (1)

Results publications

PMID 39953524